BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20733534)

  • 21. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
    Maurer MS; Raina A; Hesdorffer C; Bijou R; Colombo P; Deng M; Drusin R; Haythe J; Horn E; Lee SH; Marboe C; Naka Y; Schulman L; Scully B; Shapiro P; Prager K; Radhakrishnan J; Restaino S; Mancini D
    Transplantation; 2007 Mar; 83(5):539-45. PubMed ID: 17353770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
    Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
    Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
    Vaxman I; Dispenzieri A
    Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.
    Kim HR; Yoon SE; Kim D; Choi JO; Min JH; Kim BJ; Kim JS; Lee JE; Choi JY; Jeon ES; Kim SJ; Kim K
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):97-103. PubMed ID: 36464620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
    Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac and autologous stem cell transplantation hematopoietic in patients with AL amyloidosis.
    Carretero M; Villanueva E; Brulc EB; Faelo FM; Aguirre MA; Pérez-de-Arenaza D; Belziti CA; Arbelbide JA; Nucifora EM; Posadas-Martinez ML
    Arch Cardiol Mex; 2023; 93(4):435-441. PubMed ID: 37972368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
    D'Souza A; Dispenzieri A; Wirk B; Zhang MJ; Huang J; Gertz MA; Kyle RA; Kumar S; Comenzo RL; Peter Gale R; Lazarus HM; Savani BN; Cornell RF; Weiss BM; Vogl DT; Freytes CO; Scott EC; Landau HJ; Moreb JS; Costa LJ; Ramanathan M; Callander NS; Kamble RT; Olsson RF; Ganguly S; Nishihori T; Kindwall-Keller TL; Wood WA; Mark TM; Hari P
    J Clin Oncol; 2015 Nov; 33(32):3741-9. PubMed ID: 26371138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
    Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
    Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac and renal AL amyloidosis controlled by autologous stem cell transplantation for 17 years accompanying late onset atrial fibrillation and complete atrioventricular block.
    Iijima T; Sawa N; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Ubara Y; Ohashi K
    CEN Case Rep; 2023 Nov; 12(4):362-367. PubMed ID: 36795309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.